President Donald Trump received a dose of REGN-COV2 following an “expanded access” request from the president’s physicians.
REGN-COV2 is an investigational antibody cocktail that is in clinical trials for the treatment of COVID-19. It consists of two potent, complementary virus-neutralizing antibodies and was designed specifically to target the SARS-CoV-2 (COVID-19) virus.
Individuals interested in participating in Regeneron’s COVID-19 clinical trials can complete a screener at ClinLife.com/COVID to see if they qualify.
In Other News
1
Troy finally reopening West Main Street today; Tavern/IOOF building...
2
Coroner IDs 2 men killed in Dayton crash involving semi
3
Court rules in Ohio Renaissance Festival village detachment request
4
Bird flu spreading among dairy cows for the first time; milk supply...
5
Players Box program helping area young athletes, parents handle...
About the Author